Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab
Abstract Background Capecitabine and irinotecan combination therapy (XELIRI) has been examined at various dose levels to treat metastatic colorectal cancer (mCRC). Recently, in the Association of Medical Oncology of the German Cancer Society (AIO) 0604 trial, tri-weekly XELIRI plus bevacizumab, with...
Main Authors: | Masahito Kotaka, Ruihua Xu, Kei Muro, Young Suk Park, Satoshi Morita, Satoru Iwasa, Hiroyuki Uetake, Tomohiro Nishina, Hiroaki Nozawa, Hiroshi Matsumoto, Kentaro Yamazaki, Sae-Won Han, Wei Wang, Joong Bae Ahn, Yanhong Deng, Sang-Hee Cho, Yi Ba, Keun-Wook Lee, Tao Zhang, Taroh Satoh, Marc E. Buyse, Baek-Yeol Ryoo, Lin Shen, Junichi Sakamoto, Tae Won Kim |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2016-12-01
|
Series: | Chinese Journal of Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s40880-016-0166-3 |
Similar Items
-
Impact of prior chemotherapy with two different fluoropyrimidines on the efficacy of capecitabine plus irinotecan or FOLFIRI with or without bevacizumab in metastatic colorectal cancer: a post hoc analysis of the AXEPT study
by: Satoru Iwasa, et al.
Published: (2023-04-01) -
Case report: Changes in serum bevacizumab concentration in a hemodialysis patient with unresectable colorectal cancer treated with FOLFIRI plus bevacizumab
by: Toshimitsu Tanaka, et al.
Published: (2022-08-01) -
Switching from FOLFIRI plus cetuximab to FOLFIRI plus bevacizumab based on early tumor shrinkage in RAS wild‐type metastatic colorectal cancer: A phase II trial (HYBRID)
by: Hiroyuki Arai, et al.
Published: (2024-04-01) -
Intravitreal bevacizumab for management of choroidal osteoma without choroidal neovascularization
by: Farhad Fazel Najafabadi, et al.
Published: (2015-01-01) -
Endoglin inhibitor TRC105 with or without bevacizumab for bevacizumab-refractory glioblastoma (ENDOT): a multicenter phase II trial
by: Manmeet S. Ahluwalia, et al.
Published: (2023-09-01)